Skip to main content

Table 1 Tumor cell lines, host mice, protocol variances

From: Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages - strategies for data mining in support of therapeutic studies

Tumor typea Tumor name Histology Mouse strain Comments
Breast MCF7b Adenocarcinoma nu/nu NCr 2 samples P0, 4 samples P1
  MDA-MB-231 T Adenocarcinoma, from mouse nu/nu NCr 2 samples P0
Cervical HeLa-Luc Adenocarcinoma nu/nu NCr 2 samples P0
CNS SF-268c Anaplastic Astrocytoma NOD.SCID/NCr 2 samples P0, P4 and P10 are mouse
  SF-539c Glioblastoma NOD.SCID/NCr 2 samples P0, P4 and P10 are mouse
  U251 Glioblastoma nu/nu NCr 2 samples P0
Colon COLO 205 Adenocarcinoma nu/nu NCr  
  HCC-2998 Carcinoma nu/nu NCr  
  HCT-116 Carcinoma nu/nu NCr  
  HCT-15 Adenocarcinoma nu/nu NCr  
  HT-29 Adenocarcinoma, GR III nu/nu NCr  
  KM12 Adenocarcinoma nu/nu NCr  
  SW-620 Adenocarcinoma nu/nu NCr  
Gastric GTL 16 Adenocarcinoma nu/nu NCr 2 samples P0
Leukemia/ AS283 AIDs related Burkitts Lymphoma SCID/NCr 2 samples P0
Lymphoma CA46 B Lymphocyte Burkitts Lymphoma SCID/NCr 2 samples P0
  CCRF-CEM Acute Lymphoblastic Leukemia (T-ALL) SCID/NCr  
  HL-60(TB) Promyelocytic Leukemia SCID/NCr 3 samples P5 substituted for P4; 4 P0 samples
  K-562 Chronic Myelogenous Leukemia SCID/NCr 5 samples P5 substituted for P4, 4 samples P10
  MOLT-4 Acute Lymphoblastic Leukemia SCID/NCr  
  SR Large Cell, Immunoblastic SCID/NCr  
Liver HuH-7 Differentiated Hepatocellular Carcinoma nu/nu NCr 2 samples P0
Lung A549 Adenocarcinoma nu/nu NCr  
  A549/Asc-1 Adenocarcinoma nu/nu NCr 3 samples P4, 2 samples P0
  EKVX Adenocarcinoma SCID/NCr 2 samples P0
  HOP-62 Adenocarcinoma nu/nu NCr 4 samples P1
  HOP-92 Large Cell, undifferentiated nu/nu NCr  
  NCI-H226 Squamous Carcinoma nu/nu NCr 2 samples P1
  NCI-H23 Adenocarcinoma, NSCLC nu/nu NCr 2 samples P0
  NCI-H460 Large Cell Carcinoma nu/nu NCr  
  NCI-H522 Adenocarcinoma nu/nu NCr 2 samples P0
Melanoma A375 Metastatic Malignant Melanoma nu/nu NCr 2 samples P0
  COLO 829 Malignant Melanoma nu/nu NCr 2 samples P0
  LOX IMVI Malignant Amelanocytic Melanoma nu/nu NCr 2 samples P0
  M14 Adenocarcinoma nu/nu NCr 2 samples P0
  MALME-3 M Malignant Melanoma nu/nu NCr 2 samples P0, 4 samples P4
  MDA-MB-435 Adenocarcinoma nu/nu NCr 2 samples P0, 3 samples P10
  MDA-Nd HER2/ERB2 transfectant of MDA-MB-435 nu/nu NCr 2 samples P0
  UACC-62 Malignant Melanoma nu/nu NCr  
Ovarian CP70 Carcinoma nu/nu NCr 2 samples P0
  OVCAR-3 Adenocarcinoma nu/nu NCr 2 samples P0
  OVCAR-5 Carcinoma nu/nu NCr 2 samples P0
Pancreatic AsPC-1 Adenocarcinoma nu/nu NCr 2 samples P0
Prostate PC-3 Adenocarcinoma Male nu/nu NCr 2 samples P0
  PC-3/Me Metastatic PC-3 subline Male nu/nu NCr  
Renal 786-0 Adenocarcinoma nu/nu NCr  
  CAKI-1 Renal Cell Carcinoma nu/nu NCr 2 samples P0
  RXF 393 Poorly Differentiated Hypernephroma nu/nu NCr  
  SN12C Carcinoma nu/nu NCr 2 samples P0
  1. aTumor cells derived from the 4th in vitro passage were innoculated subcutaneously into mice. Tumors were passaged 10 consecutive times in mice. At passages 1, 4, and 10 (P1, P4, P10, respectively), 5 tumors were harvested, cut into small pieces and flash frozen in liquid nitrogen. Samples were then processed as described in Methods. For comparative purposes, 3 samples of the in vitro cultivated cells at passage 4 (P0) were also prepared for microarray analysis.
  2. b3 mg/kg Q7D SC Estradiol.
  3. cMatrigel 18.1 mg/mL P1 only.
  4. dHER2/ERBB2 transfectant of MDA-MB-435.
  5. ePC3 subline isolated from liver metastasis in mice.